Project 2: Functions of the p53 Family of Genes Arnold Levine, Ph.D. The first goal of this project is to explore the role of p53 in regulating the production of cancer stem cells and induced pluripotent stem cells (iPS). It has been shown that the absence of p53 increases the efficiency of production, reduces the time for production, and eliminates the requirement of two oncogenic transcription factors (myc and KLF-4) as fibroblasts are reprogrammed into IPS cells in culture. We have demonstrated that the loss of wild type p53 functions in cancer cells favors the reprogramming of transcriptional signatures so that cancer cells resemble embryonic stem cells and iPS cells. We are exploring the mechanisms involved in this process of cancer stem cell formation. A set of small molecular weight compounds have been identified that act in the nanomolar range as allele specific synthetic lethal drugs when applied to cells with a p53 codon 175 mutation. These drugs induce apoptosis in codon 175 containing cells, but do not act upon cells with wild type p53, and inhibit cell growth to a lesser extent in cells with other p53 mutant alleles. We are exploring the mechanism of action of this drug. Single nucleotide polymorphisms in the p63 and p73 genes of humans have been identified that act in meiosis of the parents but have phenotypes in the offspring: maternal and paternal effect genes. The phenotypes in the offspring result in higher recombination frequencies, increased copy number variations and aneuploidy. We are employing data bases to determine if such mutations in the offspring can cause cancer at young ages and uncover new tumor suppressor genes.
Maternal and paternal effect genes have been identified that can be passed down to children that possibly may be involved in the development of cancer. We are employing data bases to determine if such mutations in the offspring can cause cancer at young ages and uncover new tumor suppressor genes.
|Castillo-Martin, Mireia; Collazo Lorduy, Ana; Gladoun, Nataliya et al. (2016) H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. J Pediatr Urol 12:91.e1-7|
|Torrano, Veronica; Valcarcel-Jimenez, Lorea; Cortazar, Ana Rosa et al. (2016) The metabolic co-regulator PGC1Î± suppresses prostate cancer metastasis. Nat Cell Biol 18:645-56|
|Yoh, Kathryn E; Regunath, Kausik; Guzman, Asja et al. (2016) Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells. Proc Natl Acad Sci U S A 113:E6107-E6116|
|Levine, Arnold J; Ting, David T; Greenbaum, Benjamin D (2016) P53 and the defenses against genome instability caused by transposons and repetitive elements. Bioessays 38:508-13|
|Vidal, Samuel J; Rodriguez-Bravo, Veronica; Quinn, S Aidan et al. (2015) A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer. Cancer Cell 27:223-39|
|Zhao, Zhen; Chen, Chi-Chao; Rillahan, Cory D et al. (2015) Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet 47:539-43|
|Danielson, Laura S; Reavie, Linsey; Coussens, Marc et al. (2015) Limited miR-17-92 overexpression drives hematologic malignancies. Leuk Res 39:335-41|
|Epping, M T; Lunardi, A; Nachmani, D et al. (2015) TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFÎ² signaling activation. Cell Death Differ 22:1353-62|
|Barber, Alison G; Castillo-Martin, Mireia; Bonal, Dennis M et al. (2015) PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Med 4:1258-71|
|Chakraborty, A A; Scuoppo, C; Dey, S et al. (2015) A common functional consequence of tumor-derived mutations within c-MYC. Oncogene 34:2406-9|
Showing the most recent 10 out of 117 publications